O papel da IgG4 na fisiopatogenia da nefropatia membranosa idiopática: estado da arte
The role of IgG4 in the physiopathology of idiopathic membranous nephropathy: state of the art
Denise Maria do Nascimento Costa; Lucila Maria Valente; Gisélia Alves Pontes da Silva; Emanuel Sarinho
Resumo
Nefropatia membranosa idiopática é uma causa de síndrome nefrótica cuja etiopatogenia não está completamente esclarecida. Trata-se de uma doença imunologicamente mediada, na qual a deposição de imunocomplexos decorre da reação antígenoanticorpo in situ, na região subepitelial glomerular. A maioria dos antígenos envolvidos identificados são alvos da IgG4, subclasse predominante em imunofluorescências renais na nefropatia membranosa idiopática, em contraste com as formas secundárias da doença, nas quais IgG1, IgG2 e IgG3 prevalecem. Apesar da IgG4 ser um subtipo de imunoglobulina com baixa capacidade de ativação do complemento, há várias evidências deste envolvimento na glomerulopatia (GMP). Esses dados, em conjunto com achados de depósitos glomerulares de lectina ligadora de manose, um dos principais componentes da via das lectinas do complemento, podem sugerir que tanto a via da lectina como a IgG4 estão envolvidas nesta patologia. Os motivos que desencadeiam a formação dos imunocomplexos e a ativação das vias do complemento nesta doença são incertos. A hipótese mais aceita é a de que a nefropatia membranosa idiopática resulte do conjunto de três condições: presença de proteínas com conformações alteradas que passam a atuar como autoantígenos, anticorpos do tipo IgG4 contra estes antígenos, e susceptibilidade genética. O objetivo foi verificar o possível papel da IgG4 na etiopatogenia da nefropatia membranosa primária segundo o que foi publicado até o momento na base de dados MEDLINE/PubMed, a partir de uma revisão narrativa.
Palavras-chave
Abstract
Idiopathic membranous nephropathy is a frequent cause of nephrotic syndrome and its etiopathogenesis is not fully elucidated. In this immune mediated disease, the deposition of immune complexes is the result of an antigen-antibody reaction in situ, in the glomerular subepithelial region. Most of the antigens involved and so far identified are targets of IgG4, a predominant IgG subclass in renal immunofluorescence analysis of idiopathic membranous nephropathy, in contrast with secondary forms of the disease, in which IgG1, IgG2 and IgG3 are prevalent. Even though IgG4 is an immunoglobulin subclass with low complement activation capacity, there is abundant evidence of its involvement in the glomerulopathy. These data, together with findings of glomerular deposition of mannose-binding lectin – a major component of the lectin pathway in the complement system – may suggest that both the lectin pathway and IgG4 are involved in this pathology. The reasons behind the formation of immune complexes and the activation of complement pathways in this disease are unknown. The most widely accepted hypothesis is that idiopathic membranous nephropathy stems from a combination of three conditions: presence of proteins with altered conformations, which start to act as autoantigens; IgG4 antibodies against these antigens; and genetic susceptibility. The objective of this narrative review was to analyze the possible role of IgG4 in the etiopathogenesis of primary idiopathic membranous nephropathy based on articles published to date in the MEDLINE/PubMed database.
Keywords
Referências
1. Salant DJ. Genetic variants in membranous nephropathy: perhaps a perfect storm rather than a straightforward conformeropathy? J Am Soc Nephrol. 2013;24:525-8.
2. Glassock RJ. The pathogenesis of idiopathic membranous nephropathy: a 50-year odyssey. Am J Kidney Dis. 2010;56:157-67.
3. Diz MCE, Scherer P, Kirsztajn GM. Clinical-Epidemiological Profile of primary Membranous Glomerulopathy in Brazilian Patients (71 cases). J Bras Nefrol. 2007; 29:71-9.
4. Zeng CH, Chen HM, Wang RS, Chen Y, Zhang SH, Liu L, et al. Etiology and clinical characteristics of membranous nephropathy in Chinese patients. Am J Kidney Dis. 2008;52:691-8.
5. Maisonneuve P, Agodoa L, Gellert R, Stewart JH, Buccianti G, Lowenfels AB, et al. Distribution of primary renal diseases leading to end-stage renal failure in the United States, Europe, and Australia/New Zealand: results from an international comparative study. Am J Kidney Dis. 2000;35:157-65.
6. Malafronte P, Mastroianni-Kirsztajn G, Betônico GN, Romão JE Jr, Alves MA, Carvalho MF, et al. Paulista Registry of glomerulonephritis: 5-year data report. Nephrol Dial Transplant. 2006;21:3098-105.
7. Ronco P, Debiec H. Pathophysiological advances in membranous nephropathy: time for a shift in patient's care. Lancet. 2015 16;385:1983‑92.
8. van den Brand JA, van Dijk PR, Hofstra JM, Wetzels JF. Long-term outcomes in idiopathic membranous nephropathy using a restrictive treatment strategy. J Am Soc Nephrol. 2014;25:150-8.
9. Polanco N, Gutiérrez E, Covarsí A, Ariza F, Carreño A, Vigil A, et al. Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy J Am Soc Nephrol. 2010;21:697-704.
10. Glassock RJ. Diagnosis and natural course of membranous nephropathy. Semin Nephrol. 2003;23:324-32.
11. Sprangers B, Lefkowitz GI, Cohen SD, Stokes MB, Valeri A, Appel GB, et al. Beneficial effect of rituximab in the treatment of recurrent idiopathic membranous nephropathy after kidney transplantation. Clin J Am Soc Nephrol. 2010;5:790-7.
12. Hofstra JM, Fervenza FC, Wetzels JF. Treatment of idiopathic membranous nephropathy. Nat Rev Nephrol. 2013;9:443-58.
13. Sam R, Joshi A, James S, Jen KY, Amani F, Hart P, et al. Lupus-like membranous nephropathy: Is it lupus or not? Clin Exp Nephrol. 2015;19:395-402.
14. Murtas C, Ghiggeri GM. Membranous glomerulonephritis: histological and serological features to differentiate cancer-related and non-related forms. J Nephrol. 2016;29:469-78.
15. Ronco P, Debiec H. Pathogenesis of membranous nephropathy: recent advances and future challenges. Nat Rev Nephrol. 2012;8:203‑13.
16. Heymann W, Lund HZ, Hackel DB. The nephrotic syndrome in the rats; with special reference to the progression of the glomerular lesion and to the use of nephrotoxic sera obtained from ducks. J Lab Clin Med. 1952;39:218-24.
17. Debiec H, Guigonis V, Mougenot B, Decobert F, Haymann JP, Bensman A, et al. Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies. N Engl J Med. 2002;346:2053-60.
18. Murtas C, Bruschi M, Candiano G, Moroni G, Magistroni R, Magnano A, et al. Coexistence of different circulating anti-podocyte antibodies in membranous nephropathy. Clin J Am Soc Nephrol. 2012;7:1394‑400.
19. Beck LH Jr, Bonegio RG, Lambeau G, Beck DM, Powell DW, Cummins TD, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361:11‑21.
20. Debiec H, Lefeu F, Kemper MJ, Niaudet P, Deschênes G, Remuzzi G, et al. Early-childhood membranous nephropathy due to cationic bovine serum albumin. N Engl J Med. 2011;364:2101-10.
21. Prunotto M, Carnevali ML, Candiano G, Murtas C, Bruschi M, Corradini E, et al. Autoimmunity in membranous nephropathy targets aldose reductase and SOD2. J Am Soc Nephrol. 2010;21:507-19.
22. Bruschi M, Carnevali ML, Murtas C, Candiano G, Petretto A, Prunotto M, et al. Direct characterization of target podocyte antigens and autoantibodies in human membranous glomerulonephritis: alfa-enolase and borderline antigens. J Proteomics. 2011;74:2008-17.
23. Tomas NM, Beck LH Jr, Meyer-Schwesinger C, Seitz-Polski B, Ma H, Zahner G, Dolla G, Hoxha E, et al. Thrombospondin type-1 domaincontaining 7A in idiopathic membranous nephropathy. N Engl J Med. 2014;371:2277-87.
24. Stone JH. IgG4: a tantalizing link between causes of membranous glomerulonephritis and systemic disease. Kidney Int. 2013;83:348‑50.
25. Nirula A, Glaser SM, Kalled SL, Taylor FR. What is IgG4? A review of the biology of a unique immunoglobulin subtype. Curr Opin Rheumatol. 2011;23:119-24.
26. Aalberse RC, Schuurman J. IgG4 breaking the rules. Immunology. 2002;105:9-19.
27. Huang CC, Lehman A, Albawardi A, Satoskar A, Brodsky S, Nadasdy G, et al. IgG subclass staining in renal biopsies with membranous glomerulonephritis indicates subclass switch during disease progression. Mod Pathol. 2013;26:799-805.
28. Thurman JM, Holers VM. The central role of the alternative complement pathway in human disease. J Immunol. 2006;176:1305-10.
29. Maverakis E, Kim K , Shimoda M , Gershwin ME, Patel F, Wilken R, et al. Glycans in the immune system and The Altered Glycan Theory of Autoimmunity: a critical review. J Autoimmun. 2015;57:1-13.
30. Malhotra R, Wormald MR, Rudd PM, Fischer PB, Dwek RA, Sim RB. Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein. Nat Med. 1995;1:237-43.
31. Imai H, Hamai K, Komatsuda A, Ohtani H, Miura AB. IgG subclasses in patients with membranoproliferative glomerulonephritis, membranous nephropathy, and lupus nephritis. Kidney Int. 1997;51:270-6.
32. Kuroki A, Shibata T, Honda H, Totsuka D, Kobayashi K, Sugisaki T. Glomerular and serum IgG subclasses in diffuse proliferative lupus nephritis, membranous lupus nephritis, and idiopathic membranous nephropathy. Intern Med. 2002;41:936-42.
33. Li J, Qu Z, Zhang YM, Yu F, Huang J, Yang R, et al. Clinical significance of detection of plasma and urine IgG4 in idiopathic membranous nephropathy. Beijing Da Xue Xue Bao. 2010;42:671-4.
34. Cunningham PN, Quigg RJ. Contrasting roles of complement activation and its regulation in membranous nephropathy. J Am Soc Nephrol. 2005;16:1214-22.
35. Espinosa-Hernández M, Ortega-Salas R, López-Andreu M, GómezCarrasco JM, Pérez-Sáez MJ, Pérez-Seoane C, et al. C4d as a diagnostic tool in membranous nephropathy. Nefrologia. 2012;32:295-9.
36. Val-Bernal JF, Garijo MF, Val D, Rodrigo E, Arias M. C4d immunohistochemical staining is a sensitive method to confirm immunoreactant deposition in formalin-fixed paraffin-embedded tissue in membranous glomerulonephritis. Histol Histopathol. 2011;26:1391-7.
37. Bouwman LH, Roep BO, Roos A. Mannose-binding lectin: clinical implications for infection, transplantation, and autoimmunity. Hum Immunol. 2006;67:247-56.
38. Nauta AJ, Raaschou-Jensen N, Roos A, Daha MR, Madsen HO, Borrias-Essers MC, et al. Mannose-binding lectin engagement with late apoptotic and necrotic cells. Eur J Immunol. 2003;33:2853-63.
39. Turner MW. The role of mannose-binding lectin in health and disease. Mol Immunol. 2003;40:423-9.
40. Worthley DL, Bardy PG, Mullighan CG. Mannose-binding lectin: biology and clinical implications. Intern Med J. 2005;35:548-55.
41. Lhotta K, Würzner R, König P. Glomerular deposition of mannosebinding lectin in human glomerulonephritis. Nephrol Dial Transplant. 1999;14:881-6.
42. Segawa Y, Hisano S, Matsushita M, Fujita T, Hirose S, Takeshita M, et al. IgG subclasses and complement pathway in segmental and global membranous nephropathy. Pediatr Nephrol. 2010;25:1091-9.
43. Pucić M, Knezević A, Vidic J, Adamczyk B, Novokmet M, Polasek O, et al. High throughput isolation and glycosylation analysis of IgG-variability and heritability of the IgG glycome in three isolated human populations. Mol Cell Proteomics. 2011;10:M111.010090.
44. Klouda PT, Manos J, Acheson EJ, Dyer PA, Goldby FS, Harris R, et al. Strong association between idiopathic membranous nephropathy and HLA-DRW3. Lancet. 1979;2:770-1.
45. Vaughan RW, Demaine AG, Welsh KI. A DQA1 allele is strongly associated with idiopathic membranous nephropathy. Tissue Antigens. 1989;34:261-9.
46. Liu YH, Chen CH, Chen SY, Lin YJ, Liao WL, Tsai CH, et al. Association of phospholipase A2 receptor 1 polymorphisms with idiopathic membranous nephropathy in Chinese patients in Taiwan. J Biomed Sci. 2010;17:81.
47. Stanescu HC, Arcos-Burgos M, Medlar A, Bockenhauer D, Kottgen A, Dragomirescu L, et al. Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy. N Engl J Med. 2011;364:616‑26.
48. Coenen MJ, Hofstra JM, Debiec H, Stanescu HC, Medlar AJ, Stengel B, et al. Phospholipase A2 receptor (PLA2R1) sequence variants in idiopathic membranous nephropathy. J Am Soc Nephrol. 2013;24:677‑83.
49. Bally S, Debiec H, Ponard D, Dijoud F, Rendu J, Fauré J, et al. Phospholipase A2 Receptor-Related Membranous Nephropathy and Mannan-Binding Lectin Deficiency. J Am Soc Nephrol. 2016;27(12):3539-44.
Submetido em:
19/04/2017
Aceito em:
03/05/2017
Facebook
LinkedIn
Mendeley
StumbleUpon
Reddit
Email